BioCentury | Jan 5, 2018
Financial News

Rewind raises €15.2M series A

...A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for Drug Design and Discovery (CD3)...
BioCentury | Jan 4, 2018
Financial News

Rewind raises €15.2M series A

...A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for Drug Design and Discovery (CD3)...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...$40.8 million series A rounds, respectively (see “New Companies from New Funds”). Since then, the Center for Drug Design and Discovery (CD3)...
...London, U.K. Autolus Ltd., London, U.K. BiovelocITA s.r.l., Milan, Italy Carrick Therapeutics Ltd., Dublin, Ireland Center for Drug Design and Discovery (CD3)...
...al. “S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate.” Nature (2016) Mark Zipkin, Staff Writer Achilles Therapeutics Ltd. Autolus Ltd. Carrick Therapeutics Ltd. Center for Drug Design and Discovery (CD3) CRISPR...
BioCentury | Oct 22, 2015
Translation in Brief

Unique ubiquity

...plc (LSE:AZN; NYSE:AZN) acquired a license from the Flanders Institute for Biotechnology (VIB) and the Center for Drug Design and Discovery (CD3)...
BioCentury | Feb 10, 2014
Company News

AstraZeneca, Center for Drug Design and Discovery (CD3), Flanders Institute for Biotechnology (VIB) deal

...will be responsible for funding R&D of the compounds. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Center for Drug Design and Discovery (CD3)...
Items per page:
1 - 5 of 5
BioCentury | Jan 5, 2018
Financial News

Rewind raises €15.2M series A

...A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for Drug Design and Discovery (CD3)...
BioCentury | Jan 4, 2018
Financial News

Rewind raises €15.2M series A

...A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for Drug Design and Discovery (CD3)...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...$40.8 million series A rounds, respectively (see “New Companies from New Funds”). Since then, the Center for Drug Design and Discovery (CD3)...
...London, U.K. Autolus Ltd., London, U.K. BiovelocITA s.r.l., Milan, Italy Carrick Therapeutics Ltd., Dublin, Ireland Center for Drug Design and Discovery (CD3)...
...al. “S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate.” Nature (2016) Mark Zipkin, Staff Writer Achilles Therapeutics Ltd. Autolus Ltd. Carrick Therapeutics Ltd. Center for Drug Design and Discovery (CD3) CRISPR...
BioCentury | Oct 22, 2015
Translation in Brief

Unique ubiquity

...plc (LSE:AZN; NYSE:AZN) acquired a license from the Flanders Institute for Biotechnology (VIB) and the Center for Drug Design and Discovery (CD3)...
BioCentury | Feb 10, 2014
Company News

AstraZeneca, Center for Drug Design and Discovery (CD3), Flanders Institute for Biotechnology (VIB) deal

...will be responsible for funding R&D of the compounds. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Center for Drug Design and Discovery (CD3)...
Items per page:
1 - 5 of 5